Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trialClaudia M. Denkinger, Michael Schmitt, Maike Janssen et al.|Nature Cancer|2022Cited by 62
A prospective observational study of real-world treatment and outcome in secondary CNS lymphomaStefan Habringer, Ulrich Keller, Peter Reimer et al.|European Journal of Cancer|2023Cited by 8
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Trials|2021Cited by 7
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialClaudia M. Denkinger, Michaël Schmitt, Maike Janssen et al.|medRxiv|2022Cited by 4
S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSIONC. Müller-Tidow, Claudia M. Denkinger, Maike Janssen et al.|HemaSphere|2022Cited by 2